BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32389459)

  • 1. Negative Biopsy Histology in Men With PI-RADS Score 5 in Daily Clinical Practice: Incidence of Granulomatous Prostatitis.
    Pepe P; Pennisi M
    Clin Genitourin Cancer; 2020 Dec; 18(6):e684-e687. PubMed ID: 32389459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.
    Cash H; Günzel K; Maxeiner A; Stephan C; Fischer T; Durmus T; Miller K; Asbach P; Haas M; Kempkensteffen C
    BJU Int; 2016 Jul; 118(1):35-43. PubMed ID: 26384851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
    Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
    BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of free-hand transperineal targeted prostate biopsy using multiparametric magnetic resonance imaging-transrectal ultrasound fusion in Chinese men with prior negative biopsy and elevated prostate-specific antigen.
    Lian H; Zhuang J; Wang W; Zhang B; Shi J; Li D; Fu Y; Jiang X; Zhou W; Guo H
    BMC Urol; 2017 Jul; 17(1):52. PubMed ID: 28679370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions.
    Yaxley AJ; Yaxley JW; Thangasamy IA; Ballard E; Pokorny MR
    BJU Int; 2017 Nov; 120 Suppl 3():43-50. PubMed ID: 28749035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy.
    Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Pennisi M; Morgia G
    Scand J Urol; 2017 Aug; 51(4):260-263. PubMed ID: 28513296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
    J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which men with non-malignant pathology at magnetic resonance imaging-targeted prostate biopsy and persistent PI-RADS 3-5 lesions should repeat biopsy?
    Castellani D; Pace G; Cecchini S; Franzese C; Cicconofri A; Romagnoli D; Del Rosso A; Possanzini M; Paci E; Dellabella M; Pierangeli T
    Urol Oncol; 2022 Oct; 40(10):452.e9-452.e16. PubMed ID: 35871992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of mpMRI and PSA density in patients with an initial negative prostatic biopsy.
    Kotb AF; Spaner S; Crump T; Hyndman ME
    World J Urol; 2018 Dec; 36(12):2021-2025. PubMed ID: 29808301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cohort of transperineal electromagnetically tracked magnetic resonance imaging/ultrasonography fusion-guided biopsy: assessing the impact of inter-reader variability on cancer detection.
    Wajswol E; Winoker JS; Anastos H; Falagario U; Okhawere K; Martini A; Treacy PJ; Voutsinas N; Knauer CJ; Sfakianos JP; Lewis SC; Taouli BA; Rastinehad AR
    BJU Int; 2020 Apr; 125(4):531-540. PubMed ID: 31762182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
    Roscigno M; Stabile A; Lughezzani G; Pepe P; Galosi AB; Naselli A; Naspro R; Nicolai M; La Croce G; Aljoulani M; Perugini G; Guazzoni G; Montorsi F; Balzarini L; Sironi S; Da Pozzo LF
    Clin Genitourin Cancer; 2020 Dec; 18(6):e698-e704. PubMed ID: 32493676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combination of serum PSA assay, multi-parametric MRI and targeted prostate biopsy for prostate cancer screening in Nanjing].
    Liang J; Zhao XZ; Shi JY; Qiu XF; Zhang Q; Zhuang JL; Wang W; Deng YM; Huang HF; Zhang CW; Guo HQ
    Zhonghua Nan Ke Xue; 2019 Sep; 25(9):815-822. PubMed ID: 32233209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results.
    Tewes S; Hueper K; Hartung D; Imkamp F; Herrmann TR; Weidemann J; Renckly S; Kuczyk MA; Wacker F; Peters I
    World J Urol; 2015 Nov; 33(11):1707-14. PubMed ID: 25774003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study of artificial intelligence-guided image fusion assisted transperineal prostate biopsy].
    Hu J; Zhao XD; Zhou YL; Dong N; Ma MF; Chen YH; Sheng ZC; Dong J; He CQ; Xu S
    Zhonghua Nan Ke Xue; 2023 Aug; 29(8):729-735. PubMed ID: 38619521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central zone lesions on magnetic resonance imaging: Should we be concerned?
    Tan WP; Mazzone A; Shors S; Antoine N; Ekbal S; Khare N; McKiel C; Pessis D; Deane L
    Urol Oncol; 2017 Jan; 35(1):31.e7-31.e12. PubMed ID: 27692837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
    Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
    Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can MRI/TRUS fusion targeted biopsy replace saturation prostate biopsy in the re-evaluation of men in active surveillance?
    Pepe P; Garufi A; Priolo G; Pennisi M
    World J Urol; 2016 Sep; 34(9):1249-53. PubMed ID: 26699628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging.
    Chaloupka M; Bischoff R; Pfitzinger P; Lellig E; Ledderose S; Buchner A; Schlenker B; Stief C; Clevert DA; Apfelbeck M
    Clin Hemorheol Microcirc; 2019; 73(1):105-111. PubMed ID: 31561351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follow-up of men with a PI-RADS 4/5 lesion after negative MRI/Ultrasound fusion biopsy.
    Kornienko K; Reuter M; Maxeiner A; Günzel K; Kittner B; Reimann M; Hofbauer SL; Wiemer LE; Heckmann R; Asbach P; Wendler JJ; Schostak M; Schlomm T; Friedersdorff F; Cash H
    Sci Rep; 2022 Aug; 12(1):13603. PubMed ID: 35948575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.